CBDX — Curative Biosciences Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $0.16m
Annual income statement for Curative Biosciences, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2013 June 30th | 2014 June 30th | 2015 June 30th | 2016 June 30th | 2017 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.162 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.056 | -0.182 | 0 | — | — |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6.8 | 30 | 3.37 | 1.66 | 0.053 |
| Operating Profit | -6.64 | -30 | -3.37 | -1.66 | -0.053 |
| Net Income Before Taxes | -6.64 | -30 | -3.37 | -1.66 | -0.053 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.64 | -30 | -3.37 | -1.66 | -0.053 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.64 | -30 | -3.37 | -1.66 | -0.053 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -6.64 | -30 | -3.37 | -1.66 | -0.053 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -15.5 | -0.176 | -0.25 | -0.118 | -0.003 |
| Dividends per Share |